Healthcare provider profile · identity verified

Bryan Patrick Burns, D.O.

Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1588874366

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bryan Patrick Burns, D.O. received $35.73 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 56.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$35.73

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$20.04	56.1%	1	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$15.69	43.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$35.73	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$20.04	1	2025
Source payment records 2025-08-10 · Novo Nordisk Inc · $20.04 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	E.R. Squibb & Sons, L.L.C.	$15.69	1	2025
Source payment records 2025-09-19 · E.R. Squibb & Sons, L.L.C. · $15.69 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	198	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	198	44
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	25	11

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1200	328
Lisinopril	Lisinopril	873	241
Amlodipine Besylate	Amlodipine Besylate	719	199
Alprazolam	Alprazolam	546	111
Omeprazole	Omeprazole	525	154
Meloxicam	Meloxicam	506	161
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	454	109
Losartan Potassium	Losartan Potassium	434	121
Levothyroxine Sodium	Levothyroxine Sodium	432	116
Metformin Hcl	Metformin Hcl	321	99
Citalopram Hbr	Citalopram Hydrobromide	298	89
Simvastatin	Simvastatin	295	77
Metoprolol Succinate	Metoprolol Succinate	290	80
Tramadol Hcl	Tramadol Hcl	290	78
Hydrochlorothiazide	Hydrochlorothiazide	285	89
Gabapentin	Gabapentin	277	79
Tamsulosin Hcl	Tamsulosin Hcl	270	93
Sertraline Hcl	Sertraline Hcl	241	73
Rosuvastatin Calcium	Rosuvastatin Calcium	234	72
Trazodone Hcl	Trazodone Hcl	233	64
Glipizide	Glipizide	232	64
Metoprolol Tartrate	Metoprolol Tartrate	223	62
Pantoprazole Sodium	Pantoprazole Sodium	211	61
Eliquis	Apixaban	198	44
Furosemide	Furosemide	188	65
Zolpidem Tartrate	Zolpidem Tartrate	169	43
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	168	29
Albuterol Sulfate Hfa	Albuterol Sulfate	167	60
Duloxetine Hcl	Duloxetine Hcl	153	43
Lovastatin	Lovastatin	148	40
Pravastatin Sodium	Pravastatin Sodium	142	43
Fenofibrate	Fenofibrate	139	37
Montelukast Sodium	Montelukast Sodium	131	45
Celecoxib	Celecoxib	120	36
Potassium Chloride	Potassium Chloride	120	43
Fluticasone Propionate	Fluticasone Propionate	119	39
Spironolactone	Spironolactone	118	40
Temazepam	Temazepam	116	17
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	113	44
Carvedilol	Carvedilol	112	30
Allopurinol	Allopurinol	110	35
Diazepam	Diazepam	108	19
Prednisone	Prednisone	101	34
Metformin Hcl Er	Metformin Hcl	97	30
Lorazepam	Lorazepam	96	19
Methylprednisolone	Methylprednisolone	96	82
Clopidogrel	Clopidogrel Bisulfate	95	31
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	92	16
Escitalopram Oxalate	Escitalopram Oxalate	80	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	78	23
Azithromycin	Azithromycin	76	69
Warfarin Sodium	Warfarin Sodium	74	21
Pregabalin	Pregabalin	70	14
Famotidine	Famotidine	69	21
Alendronate Sodium	Alendronate Sodium	68	28
Buspirone Hcl	Buspirone Hcl	67	16
Donepezil Hcl	Donepezil Hcl	67	14
Mounjaro	Tirzepatide	67	14
Venlafaxine Hcl Er	Venlafaxine Hcl	67	21
Diclofenac Sodium	Diclofenac Sodium	64	15
Oxycodone Hcl	Oxycodone Hcl	64	suppressed
Bupropion Xl	Bupropion Hcl	62	16
Vitamin D2	Ergocalciferol (Vitamin D2)	58	24
Glimepiride	Glimepiride	57	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	56	46
Januvia	Sitagliptin Phosphate	54	14
Semglee (Yfgn)	Insulin Glargine-Yfgn	54	11
Clonazepam	Clonazepam	48	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	23
Ezetimibe	Ezetimibe	48	11
Finasteride	Finasteride	48	15
Atenolol	Atenolol	47	14
Bumetanide	Bumetanide	47	14
Oxybutynin Chloride Er	Oxybutynin Chloride	47	17
Quetiapine Fumarate	Quetiapine Fumarate	47	11
Torsemide	Torsemide	47	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	46	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	43	13
Methocarbamol	Methocarbamol	43	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	43	11
Doxazosin Mesylate	Doxazosin Mesylate	42	suppressed
Nebivolol Hcl	Nebivolol Hcl	42	11
Oxybutynin Chloride	Oxybutynin Chloride	41	12
Paroxetine Hcl	Paroxetine Hcl	39	12
Ibuprofen	Ibuprofen	38	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	38	12
Testosterone Cypionate	Testosterone Cypionate	38	suppressed
Valacyclovir	Valacyclovir Hcl	38	16
Amoxicillin	Amoxicillin	35	23
Trulicity	Dulaglutide	35	suppressed
Azelastine Hcl	Azelastine Hcl	34	17
Gemfibrozil	Gemfibrozil	34	suppressed
Hydralazine Hcl	Hydralazine Hcl	34	11
Estradiol	Estradiol	33	11
Mirtazapine	Mirtazapine	33	13
Sucralfate	Sucralfate	33	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	32	suppressed
Myrbetriq	Mirabegron	32	suppressed
Glipizide Er	Glipizide	31	11
Hydroxyzine Hcl	Hydroxyzine Hcl	31	suppressed
Jardiance	Empagliflozin	31	suppressed
Ramipril	Ramipril	31	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Verapamil Er	Verapamil Hcl	30	suppressed
Enalapril Maleate	Enalapril Maleate	29	suppressed
Telmisartan	Telmisartan	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	24
Fluoxetine Hcl	Fluoxetine Hcl	28	11
Folic Acid	Folic Acid	28	suppressed
Memantine Hcl	Memantine Hcl	28	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	27	27
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Latanoprost	Latanoprost	26	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	25	25
Ozempic	Semaglutide	25	11
Terazosin Hcl	Terazosin Hcl	25	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	24	suppressed
Cephalexin	Cephalexin	24	12
Levetiracetam	Levetiracetam	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	16
Metoclopramide Hcl	Metoclopramide Hcl	24	suppressed
Phenobarbital	Phenobarbital	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Valsartan	Valsartan	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Amiodarone Hcl	Amiodarone Hcl	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Ondansetron Odt	Ondansetron	22	18
Benzonatate	Benzonatate	21	15
Clonidine Hcl	Clonidine Hcl	21	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Cholestyramine	Cholestyramine (With Sugar)	20	suppressed
Levofloxacin	Levofloxacin	20	17
Nystatin	Nystatin	20	11
Prolia	Denosumab	20	15
Triamcinolone Acetonide	Triamcinolone Acetonide	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	18	suppressed
Cilostazol	Cilostazol	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Propranolol Hcl Er	Propranolol Hcl	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	16
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	11
Fentanyl	Fentanyl	16	suppressed
Nadolol	Nadolol	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	15	suppressed
Bupropion Hcl	Bupropion Hcl	15	suppressed
Insulin Aspart Flexpen	Insulin Aspart	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Liothyronine Sodium	Liothyronine Sodium	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Methimazole	Methimazole	13	suppressed
Sulfasalazine	Sulfasalazine	13	suppressed
Testosterone	Testosterone	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Glyburide	Glyburide	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Primidone	Primidone	12	suppressed
Topiramate	Topiramate	12	suppressed
Zaleplon	Zaleplon	12	suppressed
Butrans	Buprenorphine	11	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Indapamide	Indapamide	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Zolmitriptan	Zolmitriptan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$35.73 · 2 records	Novo Nordisk Inc	ELIQUIS, Wegovy	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error